232 related articles for article (PubMed ID: 18926092)
21. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
Figlin RA
Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
[TBL] [Abstract][Full Text] [Related]
22. Deforolimus (AP23573) a novel mTOR inhibitor in clinical development.
Mita M; Sankhala K; Abdel-Karim I; Mita A; Giles F
Expert Opin Investig Drugs; 2008 Dec; 17(12):1947-54. PubMed ID: 19012509
[TBL] [Abstract][Full Text] [Related]
23. [Topics in mTOR pathway and its inhibitors].
Dreyer C; Sablin MP; Faivre S; Raymond E
Bull Cancer; 2009 Jan; 96(1):87-94. PubMed ID: 19211363
[TBL] [Abstract][Full Text] [Related]
24. [Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor].
Mounier N; Vignot S; Spano JP
Bull Cancer; 2006 Nov; 93(11):1139-43. PubMed ID: 17145584
[TBL] [Abstract][Full Text] [Related]
25. The applicability of mTOR inhibition in solid tumors.
Konings IR; Verweij J; Wiemer EA; Sleijfer S
Curr Cancer Drug Targets; 2009 May; 9(3):439-50. PubMed ID: 19442061
[TBL] [Abstract][Full Text] [Related]
26. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
27. mTOR inhibitor for the treatment of hepatocellular carcinoma.
Kudo M
Dig Dis; 2011; 29(3):310-5. PubMed ID: 21829022
[TBL] [Abstract][Full Text] [Related]
28. [Everolimus (RAD001) and solid tumours: a 2008 summary].
Lévy A; Sauvin LA; Massard C; Soria JC
Bull Cancer; 2008 Dec; 95(12):1205-11. PubMed ID: 19091655
[TBL] [Abstract][Full Text] [Related]
29. mTOR signaling pathway and mTOR inhibitors in cancer therapy.
Gomez-Pinillos A; Ferrari AC
Hematol Oncol Clin North Am; 2012 Jun; 26(3):483-505, vii. PubMed ID: 22520976
[TBL] [Abstract][Full Text] [Related]
30. mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma.
Schedel F; Pries R; Thode B; Wollmann B; Wulff S; Jocham D; Wollenberg B; Kausch I
Oncol Rep; 2011 Mar; 25(3):763-8. PubMed ID: 21240463
[TBL] [Abstract][Full Text] [Related]
31. Current status and challenges associated with targeting mTOR for cancer therapy.
Dowling RJ; Pollak M; Sonenberg N
BioDrugs; 2009; 23(2):77-91. PubMed ID: 19489650
[TBL] [Abstract][Full Text] [Related]
32. Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.
Sankhala K; Giles FJ
Expert Rev Hematol; 2009 Aug; 2(4):399-414. PubMed ID: 21082945
[TBL] [Abstract][Full Text] [Related]
33. [Antitumoral effect of proliferation signal inhibitors].
Dumortier J
Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S263-7. PubMed ID: 20004333
[TBL] [Abstract][Full Text] [Related]
34. Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations.
Boni JP; Hug B; Leister C; Sonnichsen D
Semin Oncol; 2009 Dec; 36 Suppl 3():S18-25. PubMed ID: 19963096
[TBL] [Abstract][Full Text] [Related]
35. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis.
Seeliger H; Guba M; Kleespies A; Jauch KW; Bruns CJ
Cancer Metastasis Rev; 2007 Dec; 26(3-4):611-21. PubMed ID: 17713840
[TBL] [Abstract][Full Text] [Related]
36. The potential role of mTOR inhibitors in non-small cell lung cancer.
Gridelli C; Maione P; Rossi A
Oncologist; 2008 Feb; 13(2):139-47. PubMed ID: 18305058
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
38. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.
Shor B; Zhang WG; Toral-Barza L; Lucas J; Abraham RT; Gibbons JJ; Yu K
Cancer Res; 2008 Apr; 68(8):2934-43. PubMed ID: 18413763
[TBL] [Abstract][Full Text] [Related]
39. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.
Huang S; Houghton PJ
Curr Opin Investig Drugs; 2002 Feb; 3(2):295-304. PubMed ID: 12020063
[TBL] [Abstract][Full Text] [Related]
40. Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.
Diaz-Padilla I; Duran I; Clarke BA; Oza AM
Cancer Treat Rev; 2012 Oct; 38(6):767-75. PubMed ID: 22381585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
